Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Yuko Tsuchiya-KawanoTomonari SasakiHiroyuki YamaguchiKatsuya HiranoAtsushi HoriikeMiyako SatouchiShinobu HosokawaRyotaro MorinagaKazutoshi KomiyaKoji InoueYuka FujitaRyo ToyozawaTomoki KimuraKosuke TakahashiKazuo NishikawaJunji KishimotoYoichi NakanishiIsamu OkamotoPublished in: The oncologist (2019)
Concurrent chemoradiation with nab-P/C was safe and provided a long-term survival benefit for patients with locally advanced NSCLC.
Keyphrases
- locally advanced
- advanced non small cell lung cancer
- phase ii study
- rectal cancer
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- squamous cell carcinoma
- radiation therapy
- electronic health record
- tyrosine kinase
- big data
- early stage
- randomized controlled trial
- free survival
- data analysis
- chemotherapy induced
- double blind